Loading quotes...

Forecast

There is no analyst data available for this company.

News Go to news feed

Dermapharm: profit growth in H1 2026 drives EBITDA margin and cash flow significantly higher

Dermapharm reports a revenue increase of around 5% in H1 2026 and adjusted EBITDA growth of about 14%, lifting the EBITDA margin by 2 percentage points. Stronger branded drug sales and an improved cash conversion of 65% offset a EUR 30m write-down on a receivable from the Dutch cannabis business. Operating cash flow rose by EUR 35m, free-cash-flow yield stands at 12%; management confirmed the full-year forecast but does not expect to exceed it. The share price rose moderately, while higher leverage after share buybacks and an ongoing BaFin review were cited as risks. » More on de.investing.com
Dermapharm grows thanks to branded medicines and acquisitions and confirms annual targets

Dermapharm reports momentum in the second quarter driven by branded medicines and the acquisitions of Mucos and F. Trenka. Revenue rose in the first half by 2.9% to €591.0 million, adjusted EBITDA climbed to €163.2 million and the margin to 27.6%. The group confirms its 2026 guidance (revenue €1.182–1.218 billion; adjusted operating profit €331–341 million). Analysts reacted positively, while BaFin is conducting a review of the 2025 financial statements. » More on finanzen.net
Dermapharm confirms full-year targets after growth from branded medicines and acquisitions

Dermapharm reported first-half sales up 2.9% to €591.0m and an adjusted EBITDA of €163.2m, with the margin rising to 27.6%. Drivers were organic growth in branded medicines and the acquisitions of Mucos and F. Trenka, while Arkopharma performed more weakly. The company confirms its 2026 full-year guidance of €1.182–1.218bn in sales and an adjusted operating result of €331–341m. BaFin has meanwhile opened reviews of the 2025 annual financial statements. » More on finanzen.net

Historical dividends Dividends

All dividend metrics All metrics

In 2026, Dermapharm Holding has already paid €0.88 in dividends. The last payout was in July.

Financials

In the last quarter, Dermapharm Holding had revenue of €285.15m and net profit of €23.22m

(EUR)	June 2026	YoY
Revenue	285.15m	4.78%
Gross profit	95.14m	48.33%
Net profit	23.22m	11.15%
EBITDA	71.05m	8.04%

Fundamentals

Metric	Value
Market capitalization	€1.91bn
Number of shares	49.54m
52-week high/low	€51.90 - €32.90
Dividend yield	2.28%
Dividends TTM	€0.88
Beta	0.87
P/E ratio	13.92
PEG ratio	0.36
P/B ratio	3.56
P/S ratio	1.62

Company profile

Dermapharm Holding SE, together with its subsidiaries, engages in the off-patent branded pharmaceuticals business in Germany and internationally. It operates through three segments: Branded Pharmaceuticals and Other Healthcare Products, Parallel Import Business, and Herbal Extracts. The company develops, manufactures, licenses, markets, and sells branded generics, over-the-counter drugs, non-prescription natural remedies, and other healthcare products. It also offers healthcare products in the areas of vitamins, minerals, food supplements, dermatology, allergology, pain and inflammation treatment, cardiovascular support, gynecology, and urology primarily under the Dekristol, Dekristolvit, Allergovit, and Tromcardin brands. In addition, the company provides medical devices under the bite away and Herpotherm names; Momekort, a nasal spray used to treat allergy symptoms; and Azedil, a nasal spray or eye drop. Further, it imports originator pharmaceuticals under the axicorp brand; and offers herbal extracts and natural active ingredients for phytopharmaceuticals, nutraceuticals, and cosmetics. It serves pharmaceutical wholesalers, pharmacies, hospitals, and health food stores. The company was founded in 1991 and is headquartered in Grünwald, Germany. Dermapharm Holding SE is a subsidiary of Themis Beteiligungs-Aktiengesellschaft.

Name	Dermapharm Holding
CEO	Hans-Georg Feldmeier
Headquarters	Grünwald, bv Germany
Website	dermapharm.de
Sector	Health Care
Industry	Pharmaceuticals
IPO	12/04/2018
Employees	3,619